Archives
-
p38α Dephosphorylation and Dual-Action Kinase Inhibitors
2026-09-20
The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phosphothreonine and accelerate its removal by the phosphatase WIP1. Structural and biochemical evidence establishes kinase conformation as a potential lever for improving inhibitor selectivity, potency, and control of signaling duration.
-
SkQ1, Apoptosis, and Muscle Atrophy in Ovarian Cancer
2026-09-19
This preprint uses a metastatic ovarian cancer mouse model and chronic SkQ1 treatment to test whether mitochondrial reactive oxygen species, apoptotic caspases, or necroptosis contribute to skeletal muscle atrophy. SkQ1 reduced mitochondrial hydrogen peroxide emission and caspase-9/-3 activity without preventing gastrocnemius atrophy, separating mitochondrial apoptotic signaling from muscle wasting in this model.
-
Ruxolitinib Phosphate: JAK Signaling to Cell Fate
2026-09-18
Ruxolitinib phosphate and INCB018424 provide a precise entry point for studying JAK1/JAK2-dependent cytokine signaling. This article translates recent anaplastic thyroid carcinoma findings into a phenotype-first framework for designing, controlling, and interpreting pathway-modulation assays.
-
Dabigatran Etexilate: Precision in Thrombin Research
2026-09-18
Dabigatran etexilate offers translational researchers a mechanistically defined way to study thrombin-driven coagulation, platelet activation, atrial fibrillation, and stroke risk. This thought-leadership perspective connects direct thrombin inhibition with experimental design, competitive positioning, and practical workflow decisions.
-
Metoprolol Research: From Receptor Blockade to Assay Design
2026-09-17
Metoprolol is a selective beta1-adrenoceptor antagonist with applications spanning cardiovascular disease research and mechanistic studies of inflammation, cancer, and angiogenesis. This article explains how integrated pharmacokinetic evidence can improve assay architecture, controls, and interpretation without confusing findings from MASH models with Metoprolol-specific evidence.
-
High-Content Stem Cell Screening in Schistosoma
2026-09-17
Perera, Chioni, and Walker developed a quantitative high-content assay that measures somatic neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. Screening a 280-compound stem cell-focused collection identified prioritized molecules that disrupted parasite development and stem cell proliferation, offering a more informative route to anti-schistosomal lead discovery than morphology or motility alone.
-
ML-7 Hydrochloride: From MLC Signal to Assay
2026-09-16
ML-7 hydrochloride is a myosin light chain kinase inhibitor for dissecting MLC phosphorylation, contractility, barrier function, and cell invasion. This article presents an assay-first framework that connects cardiovascular models with mechanistic insights from breast cancer research.
-
NF 340: Mapping P2Y11 Signaling in Invasion
2026-09-16
Explore how the P2Y11 antagonist NF 340 helps dissect the connection between QPRT, purinergic signaling, and myosin light-chain phosphorylation. This guide translates the reference study into practical assay decisions while clarifying compound handling, controls, and interpretation limits.
-
15-PGDH Inhibition Preserves Muscle During Weight Loss
2026-09-15
The reference study shows that inhibiting 15-PGDH can improve muscle regeneration and strength recovery during semaglutide-associated weight loss in obese mice. Its central advance is the combination of a GLP-1 receptor agonist with a regenerative intervention that improves postinjury muscle quality without reducing weight-loss efficacy.
-
Crizotinib in Patient-Derived Cancer Assembloids
2026-09-15
Patient-derived gastric cancer assembloids expose how stromal context can reshape drug response. This thought-leadership guide shows how Crizotinib hydrochloride can be positioned as a mechanistic probe for ALK, c-Met, and ROS1 signaling in more physiologically relevant cancer biology research.
-
Z-VAD-FMK Workflow for Apoptosis and Ferroptosis
2026-09-14
Z-VAD-FMK turns a cell-death assay into a causal test: block caspase-dependent apoptosis while independently tracking the TFEB–NRF2 ferroptosis axis described in NSCLC. This workflow combines practical dosing and stock-handling guidance with controls that distinguish pathway rescue from nonspecific cytoprotection.
-
Cell Cycle Assay Kit for Cancer Cell-Cycle Analysis
2026-09-14
Use DNA-content profiling to distinguish G0/G1, S, and G2/M populations while flagging apoptotic sub-G1 events in treatment-response studies. This practical workflow shows how to apply PI/RNase A staining to colorectal cancer experiments inspired by recent CGF research, with controls and troubleshooting built in.
-
Verapamil HCl Workflows for Calcium Signaling
2026-09-13
Verapamil HCl provides a practical perturbation tool for L-type calcium channel studies, with applications spanning calcium channel inhibition in myeloma cells, transporter biology, and inflammatory disease models. This guide translates the evidence into staged assay workflows, controls, and troubleshooting decisions for more reproducible results.
-
Carfilzomib (PR-171): A Proteostasis Assay Guide
2026-09-12
Carfilzomib (PR-171) is an irreversible proteasome inhibitor whose value extends beyond simple viability testing. This guide develops a mechanism-to-readout framework linking proteasome-mediated proteolysis inhibition with ER-stress biomarkers, apoptosis interpretation, and combination-assay design.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-09-11
Wang et al. identify a METTL16–SENP3–LTF axis that lowers the labile iron pool and protects hepatocellular carcinoma cells from ferroptosis. By integrating m6A-focused molecular assays with organoids, xenografts, genetically modified mice, and human samples, the study connects RNA regulation, protein stability, iron handling, and tumor progression.